Tocilizumab Efficacy, Safety Sustained at 2 Years in sJIA
CHICAGO – Tocilizumab remained highly effective with a favorable risk-benefit ratio after 2 years of continuous treatment in 61 patients with severe, refractory systemic juvenile idiopathic arthritis, findings from the ongoing phase III TENDER trial show.
From the Annual Meeting of the American College of Rheumatology
PREVIEW